Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Biotech is a really slow burn most of the time, and so it begins here.
Sold to take the huge tax losses, that and the call options losses.
See everyone in 2 years after the dilution and when P3 results get closer.
For what it's worth, I think if they kept the original duration they would have been more successful. I didn't catch they were only powering it to .1 - Who the eff would do this, when it just means even with good results you will guarantee 'failure' by not meeting acceptable stat sig, I don't care how much more it costs you, it will cost you more in lost stock price. Yes I get the bear thesis that they do this intentionally to cover bad results, so hope I've covered that for the conspiracy theorists.
How was this never mentioned before? This seems like a huge indication on its own. Even going back and reviewing the cancer data and putting together a poster presentation for a medical conference, seems like this could be easily done.
New TED talk today at TED 2017 about Alzheimers
https://www.ted.com/talks/lisa_genova_what_you_can_do_to_prevent_alzheimer_s
I don't think a stop loss is applicable in all scenarios, especially this one.
How is a stop loss going to protect you during a binary event, when the price immediately moves from say, $20 to $1. There are no buyers at your stop loss of $15 since the price skipped right over it.
600 shares 3 options. I guess let's do this.
It doesn't even matter. Anytime there is a huge drop there will be ambulance chasers that find something looking for a settlement.
Squeezing the cheeks so hard right now... hnnngg.
Stop losses totally pointless when price will jump immediately and you will have no chance to get out or in either way.
Someone wake me when it's over.
Why would you hedge if you already know the outcome? Seems like a huge waste of money.
No one is questioning $100m. They have authorised 150m shares, which at $20/share is $3 billion. That is a big difference. Maybe they sell some to BP, but it really seems like you could make that change when you need it.
Here is a copy/paste from the 8-K: https://www.sec.gov/Archives/edgar/data/1513856/000114420417011005/v460054_8k.htm
"On February 17, 2017, at a special meeting of stockholders (the “Special Meeting”) of Neurotrope, Inc. (the “Company”), the stockholders of the Company approved an amendment to the Company’s Articles of Incorporation (the “Charter”), to be effective immediately, to increase the number of authorized shares of our common stock to 150,000,000 shares. The amendment was filed with the Secretary of State of the State of Nevada on February 24, 2017."
So again, why do they need up to $3b at current share price? If they expect good results, 150m shares will result in more than $3b.
150m shelf registration
Is there anyone that would defend this share authorisation / shelf, as normal? The amount seems huge in proportion to the money needed to even finish multiple phase 3 trials, which let's say are $1B each!
IR maintains this amount is perfectly normal and everyday occurrence for any company, and absolutely nothing wrong with it.
Are they just completely oblivious and/or covering for something? There's no way this amount is normal.
1500 cancer patients were on high doses, some for over a year. I don't get the safety concerns people have here. Sure maybe it doesn't end up working, but I think the safety is generally pretty well tested by now. It would be even easier to see a 'brain' related safety issue in cancer patients, because if you've ever been around a person with AD, it's brain degradation... you never know if it's just one more thing that has gone, or maybe the drug. I'm much more satisfied with safety data from people with cancer, where they have their faculties, so if you see something 'brain' related (sorry for just dumbing this down) you might think, hey this is because of the drug.
I think the short trial is to see quickly if it has an effect as theorized and confirm the results of the CU patients, and be able to get to an actual P3 and partner in the quickest amount of time.
Also, I don't know how many of you have ever had a close family member with AD, but I can tell you with 100% certainty that we would have paid $1500 for just one day of greater clarity, to have the person back for just one moment. If it "only" works for three months and shows any improvement would truly have been a miracle to us. The bar is really low here.
Where are you getting any of this, or are you just making it up?
$ntrp bryo ineffective at overall survival rate
increased tau hyperphosphorylation
continuing amyloid cascade
increased demyelination and onset of paralysis
That is not correct. The FDA just needs to approve the open extension, that's all. It might have already been approved.
but those patients won't be able to continue on the drug until AFTER the drug is FDA approved. Is that correct?
I've been informed by a neurologist that unregulated synaptogenesis has a downside, increased incidence of seizures and behavioral/psyche issues for people that have Alzheimers.
Bryostatin does not at all address/correct mitochondrial dysfunction. Many Alzheimers experts describe Alzheimers as a "mitochondrial dysfunction disease".
The sigma 1 drugs show correction of mitochondrial dysfunction (neuroprotection) and also boost synaptogenesis (neurorestoration), tho their synaptogenesis is more measured and regulated for when the neurons need it. Sigma 1 drugs stimulate PKC via M1 receptor stimulation and via releasing calcium from IP3 channels as needed. Sigma drugs treat microglial cells and oligodendrocytes, not just neurons.
This is all about plaques, which has never worked so far. We need the proof synaptogenesis is improving some mammals/humans.
With the diluted shares it's really 14m shares and ~$280m market cap at about $20 a share I think.
NTRP looks opposite to what you are describing, except for the high inside ownership.
NTRP is not dragging out the process. They executed a relatively quick blinded placebo controlled trial. If they wanted to drag it out they would have done more safety studies that weren't designed as powered studies or with enough drug to show efficacy, again, to drag things out. They would have done it in mildly affected patients where it's hard to tell if they have Alz, and hard to tell if it's effective or not since the people are kind of still ok. If this study fails, their large inside ownership will quickly become almost worthless and they walk away with Nothing.
I don't see the scam here. They didn't leave themselves room to execute on the scam; none of the other requirements have been put in place.
I am invested in other biotechs where there are stock incentives to management. The "goals" are easily set by the same management and met 100% each year, even though the stock actually lost value, since conveniently that was not one of the goals to increase shareholder value. So among other reasons, I don't really care about this point since it can be manipulated just as much when the management and board are all fellows of the Executive Club that like to scratch each other's backs.
Unfortunately, this does seem to be the way NTRP is working out.. High insider ownership, whereas that "other" stock has high retail ownership backed by stock incentives to management.
Quote:
Some bio investors are only looking at how long the process can be drug out. It is like a ponzi scheme, where they get in low, the company runs endless meaningless trials. The retail investors get sucked in and the low price insider and option holders walk away in a few years with money in the bank.
Low float for now. They have that huge # of shares authorised and ready to dilute. Then there's the possible partnership deal. How much cash does the partner take; could be another big haircut on future profits. How much $ is everyone investing to make this a life changer?